Document is current
Any future updates will be listed below
-
Authors
Bergqvist, Karin
Imberg, Henrik
Hallström, Sara
Michelsen, Jens
Liljebäck, Hanna
Franzén, Stefan
Norhammar, Anna
Rosengren, Annika
Lind, Marcus
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 14 February 2026
Accepted: 26 July 2026
First Online: 24 August 2026
Declarations
Ethics approval and consent to participate: All patients in the NDR provided informed consent to be included in the register. The study was approved by the Swedish Ethical Review Authority.
Competing interests: KB has no competing interests to declare. HI has no conflict of interest. SH has lectured for Novo Nordisk. JM has no conflict of interest. HL has no conflict of interest. SF is an employee of AstraZeneca and holds shares in AstraZeneca. AR has no competing interest to declare. AN has been consultant and received honoraria from AstraZeneca, Novo Nordisk, MSD and Boehringer Ingelheim. ML has received research grants from Eli Lilly and Novo Nordisk and been consultant or received honoraria from Boehringer Ingelheim, Eli Lilly, Nordic Infucare, Novo Nordisk and Rubin Medical, all outside the submitted work.
